Posted by Michael Wonder on 01 May 2022
Schedule of Pharmaceutical Benefits - 1 May 2022
1 May 2022 - The May 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The May issue of the Schedule includes a few revised listings:
- Apalutamide (Erlyand) - new medicine
- Budesonide (Joreveza) - new indication
- Buprenorphine (Buvidal) - new strength
- Elotuzumab (Empliciti) - new medicine
- Nintedanib esylate (Ofev) - new indication
- Nirmatrelvir and ritonavir (Paxlovid) - new combination product
- Onasemnogene abeparvovec (Zolgensma) - new gene therapy
- Sacituzumab govitecan (Trodelvy) - new medicine
- Asfotase alfa (Strensiq) - new medicine (LSDP listing)
